tlooto
Sign up
Medicine

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

Timothy M. Smith, A. Befeler

2007.3.1Current Gastroenterology Reports

DOI: 10.1007/s11894-008-0021-z

tlooto Summary

The majority of trials using UDCA in PSC are underpowered and fail to show improvements in clinically relevant endpoints, such as delayed progression to cirrhosis, portal hypertension, liver transplantation, development of cholangiocarcinoma, or death.

Abstract

Abstract is not available.

Citation format

SMITH, Timothy M.; BEFELER, A. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Current Gastroenterology Reports, 2007, 9: 54–59.